艾昆緯 IQV 深 滬
等待開盤 10-08 09:30:00 美东时间
258.11
-1.870
-0.72%
華盛通- 最 高261.41
- 今 開261.41
- 成交量 140.60万股
- 最 低 255.05
- 昨 收 259.98
- 總市值 4248.49万
- 52周最高 277.40
- 市盈率 靜 32.93
- 換手率 854.22%
- 52周最低 154.50
- 委 比 67.21%
- 總股本 0.00亿
- 歷史最高 285.61
- 量 比 0.98
- 振 幅 2.45%
- 歷史最低 81.79
- 每 手 1
- 風險率 33.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $300
Barclays analyst Luke Sergott maintains IQVIA Holdings (NYSE:IQV) with a Overweight and raises the price target from $275 to $300.
10-07 22:54
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Arbli™, a novel losartan potassium oral suspension, has been added to the formularies of three leading U.S. pediatric medical centers, expanding its presence in pediatric care. This milestone follows sequential increases in wholesale orders and reflects growing adoption across healthcare channels. Targeting a $219 million U.S. market with 72 million annual prescriptions, Arbli™ offers a consistent, convenient alternative to pharmacy compounding, ...
10-02 12:05
Stock futures rise as Treasury yields take a breather
Stock index futures were higher on Wednesday as the recent rally in Treasury yields looked to take a breather, while traders turned their focus to several key economic reports. Wall Street’s major mar...
09-30 16:10
美股大行评级 | 潜在涨幅919.61%！HC Wainwright上调NeuroSense Therapeutics目标价至52美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持NeuroSense Therapeutics"买入"评级，目标价从8美元升至52美元；HC Wainwright & Co.：维持艾切托"买入"评级，目标价从27美元升至34美元
09-29 08:33
Truist Securities Reiterates Buy on IQVIA Holdings, Raises Price Target to $329
Truist Securities analyst Jailendra Singh reiterates IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $300 to $329.
09-28 23:13
SCIENTURE To Provide REZENOPY To Addiction Treatment Centers
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in...
09-22 20:16
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Amneal Pharmaceuticals announced FDA approval of its lanreotide injection, a long-acting treatment for acromegaly, neuroendocrine tumors, and carcinoid syndrome. The product, referencing SOMATULINE® Depot, received Competitive Generic Therapy (CGT) designation and will launch immediately. With in-house manufacturing, Amneal aims to broaden access and deliver long-term value. U.S. annual sales for SOMATULINE® Depot were $983 million in 2026, per I...
09-18 20:01
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Morgan Stanley Maintains Equal-Weight on IQVIA Holdings, Raises Price Target to $270
Morgan Stanley analyst Kallum Titchmarsh maintains IQVIA Holdings (NYSE:IQV) with a Equal-Weight and raises the price target from $240 to $270.
09-17 23:52
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
LB Pharmaceuticals Inc announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, including schizophrenia, mood disorders, and neurodegenerative diseases. She previously led clinical development at Intra-Cellular Therapies and Centessa Pharmaceuticals. LB Pharmaceuticals is advancing its Phase 3 NOVA-2 trial for LB-102, a potential first be...
09-15 12:00
